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Abstract: This review summarizes the current knowledge pertaining to Kaposi  
sarcoma-associated herpesvirus (KSHV) epidemiology and transmission. Since the 
identification of KSHV twenty years ago, it is now known to be associated with Kaposi’s 
sarcoma (KS), primary effusion lymphoma, and multicentric Castleman’s disease. Many 
studies have been conducted to understand its epidemiology and pathogenesis and their 
results clearly show that the worldwide distribution of KSHV is uneven. Some geographical 
areas, such as sub-Saharan Africa, the Mediterranean region and the Xinjiang region of 
China, are endemic areas, but Western Europe and United States have a low prevalence in 
the general population. This makes it imperative to understand the risk factors associated 
with acquisition of infection. KSHV can be transmitted via sexual contact and non-sexual 
routes, such as transfusion of contaminated blood and tissues transplants, or via saliva 
contact. There is now a general consensus that salivary transmission is the main route of 
transmission, especially in children residing in endemic areas. Therefore, there is a need to 
better understand the sources of transmission to young children. Additionally, lack of 
animal models to study transmission, gold standard serological assay and the lack of 
emphasis on endemic KS research has hampered the efforts to further delineate KSHV 
transmission in order to design effective prevention strategies.  
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1. Introduction 
Human herpesviruses are large double stranded DNA viruses that are ubiquitous in nature. Of the 
eight known human herpesviruses two have been implicated to be the etiologic agents for a number of 
cancers, Epstein-Barr virus, and the Kaposi sarcoma-associated herpesvirus (KSHV). Since its 
identification in 1994, KSHV is known to be associated with all forms of Kaposi’s sarcoma (KS) 
primary effusion lymphoma and multicentric Castleman’s disease [1–4]. KS is an AIDS-defining 
illness and is the most common malignancy present in HIV-1 infected patients [5]. One of the earliest 
indicators of the upcoming HIV/AIDS epidemic was the sudden appearance of KS and high-grade 
non-Hodgkin’s lymphoma in young men having sex with men (MSM) [6].  
Since KSHV DNA cannot be detected in all infected individuals, a serological assay to detect the 
presence of antibodies against KSHV is the method of choice to investigate KSHV prevalence in a 
population. Unlike EBV, global seroprevalence of KSHV varies greatly and is generally high in areas 
where non-HIV associated forms of KS (classic or endemic forms) have been common [7]. These 
areas include African and Mediterranean regions, where KSHV seroprevalence ranges from 20% to 
80% in the adult populations, whereas seroprevalence in the United States and Northern Europe is 
generally low (<10%) [8–14]. In South America, the Amerindians have also been identified as a 
hyperendemic population for KSHV infection [15]. Interestingly, the prevalence in the non-
Amerindians is significantly lower. de Souza et al. have recently reported that >70% of children  
(four to nine years) were positive for KSHV and the prevalence increased with age (>90% in >40 year 
age group) [16]. This pattern is strikingly similar to Africa, where infection seems to occur in early 
childhood. In contrast, KS incidence is uncommon and KSHV prevalence is low in most Asian 
countries [17]. However, in China, KSHV prevalence varies considerably between different regions of 
the country and is between 7.3% percent and 16.1 percent in adults in different provinces [18–21]. In 
particular, the prevalence was found to be high in the Xinjiang province, which is located in the 
northwestern region of China. Interestingly, cases of both classic KS and AIDS-associated KS are 
found mostly in the Uyghurs and the Kazakh ethnicities [20,21]. The reasons for such geographical 
and population variations of KS and KSHV distribution remain to be addressed.  
Our laboratory has conducted extensive cohort studies in Zambia, a sub-Saharan African country. 
Zambia has been considered as part of the “KS belt”, where endemic KS was prevalent and where 
significant increase in KS incidence in adults and children has coincided with the emergence of the 
HIV-1 epidemic [22–24]. This increase in KS incidence is significant because, by 1992, KS accounted 
for approximately 25% of all childhood cancers diagnosed in Lusaka, the capital of Zambia [25]. This 
review summarizes some of the results of our cohort studies in Zambia, together with those from other 
significant studies that have contributed to further our understanding of KSHV transmission and 
pathogenesis, and, more importantly, explore some of the questions that still remain unanswered and 
warrant further research.  
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2. Modes of Transmission 
Primary KSHV infection can occur during childhood and as an adult and can be transmitted via 
both sexual and non-sexual routes. KSHV can be found in the peripheral blood mononuclear cells 
(PBMCs), saliva, oropharyngeal mucosa, semen, cervico-vaginal secretions, and prostate glands, 
which may represent the source of both vertical and horizontal transmission [26–29]. The modes of 
transmission of KSHV may vary in different parts of the world, depending on the endemicity of that 
region. In non-endemic areas, especially in adults, sexual transmission (homosexual and heterosexual) 
of KSHV may be the route of transmission [30–32]. However, there is limited information about this 
route and further extensive studies are needed. Studies have shown that sexual transmission, 
particularly among MSMs, may play a major role in transmission in non-endemic areas, such as the 
United States and Western Europe, because the seroprevalence among MSMs is significantly higher as 
compared to the general population. In the San Francisco Mens Health Study, the prevalence of KSHV 
infection was reported to be high among MSMs (37.6%) when compared to heterosexual men (no 
prevalence in this group) [31]. They also reported an association of KSHV prevalence with the number 
of sexual partners. Other studies have reported that besides the number of sex partners, syphilis 
infection and hepatitis B infection are also risk factors for acquisition of infection [27,31,33,34]. 
However, the possibility of sexual transmission among heterosexual individuals remains unclear. 
Different studies have been inconsistent about the evidence of transmission through heterosexual 
contact. This can be explained in part by the populations that were investigated. Two African studies 
have been conducted in commercial sex workers in Nigeria and Kenya, and clearly suggest sexual 
transmission occurring in the adult population [35,36]. Another study conducted in truckers in Kenya 
also suggest that there is ongoing sexual transmission during adulthood [37]. However, there are other 
studies that do not observe any evidence of sexual transmission [38,39]. One of them is a study 
conducted by Malope et al., in South Africa. This is an interesting study because it had a large sample 
size and sampling was conducted from miners, sex workers, and other residents of the city. This study 
did not find any association of KSHV prevalence with sexual behavior. In addition, our study 
conducted in a group of female sex workers in China showed KSHV prevalence of 10%, which is 
similar to the general women population, even though the prevalence of other sexually transmitted 
infections (STI), such as HSV-2 and syphilis, were higher than the general women population. Our 
study suggested that heterosexual transmission may not be a dominant route for KSHV, at least among 
Chinese women [40]. Another important issue while investigating sexual transmission is that both 
kissing and salivary exchange during hetero and homosexual contact is common. This makes it harder 
to delineate whether the transmission was sexual or oral through saliva. Additionally, it is important to 
consider that all these studies were cross-sectional in design. Longitudinal cohort studies that can 
follow individuals for seroconversion and incident infection are needed to truly understand the impact 
of this route of transmission. 
Besides sexual transmission, another possible horizontal transmission route is via KSHV 
contaminated blood transfusion because viral DNA may be detected in 10–15 percent of PBMCs of 
healthy KSHV seropositive individuals [41,42]. Transmission of KSHV via this route is likely to be 
inefficient because of the cell associated nature of the virus, and viremia is uncommon, even in KSHV 
infected individuals. However, blood transfusion has recently been investigated in an elegant study by 
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Hladik et al., where they provided strong evidence that KSHV can be transmitted by blood transfusion 
[43]. This study was conducted in Uganda, where 991 KSHV seronegative recipients were followed 
after transfusion. Among them, 425 patients received KSHV seropositive blood and 566 patients 
received KSHV seronegative blood. They observed that KSHV seroconversion occurred in 41 of the 
991 recipients. The excess risk of KSHV seroconversion after transfusion with KSHV seropositive 
blood (during the observed 24-week follow-up) was 2.8%. This suggests that 12 patients (of the 425 
patients exposed to KSHV seropositive blood) were infected by transfusion. Another interesting result 
of this study was that an excess risk of 4.2% was observed among patients who received blood stored 
for less than four days as compared to those who received blood stored for more than four days. The 
results from this study led them to further investigate whether transfusion of KSHV positive blood led 
to an increase in mortality. Their results show that transfusion of short stored blood was associated 
with increased risk of death (adjusted hazard ratio – 1.79) [44]. Whether the increased risk was due to 
KSHV or other factors in short stored blood will need to be further investigated. 
After KSHV was identified, several observations and published studies led researchers to 
hypothesize that KSHV can be transmitted by another non-sexual route, specifically from mother to 
child vertically. The high seroprevalence level in children, especially in endemic areas was one of the 
rationales. Additionally, KSHV has been found in cervico-vaginal secretions of HIV-1 and KSHV 
co-infected women, suggesting that KSHV viral load in the female genital tract might influence the 
vertical transmission of KSHV [45]. Moreover, development of KS in children less than one year of 
age was indicative of perinatal transmission [46]. These observations also formed the basis of our 
cohort study conducted between 1998 and 2004. Pregnant mothers in early stages of labor were 
recruited in the cohort and both the mother and infant were enrolled and followed after delivery. 
Vertical transmission was investigated in 89 mother-infant pairs. All of these 89 children were born to 
KSHV seropositive mothers whose serostatus was tested at the time of delivery [28]. We have reported 
that KSHV DNA was detected in PBMCs in 2/89 children within 24 h after birth. More recently, 
Lisco et al. have addressed this question from a different perspective [45]. As herpesvirus reactivation 
occurs during pregnancy, they investigated the KSHV presence and viral load in PBMCs and 
cervicovaginal secretions (CVS) from 15 pregnant Italian women. They have reported viral 
reactivation in 5/15 women in PBMCs and CVS. One infant also had the same viral subtype as the 
mother at two months after birth. Together, these reports strongly indicate that in utero or intrapartum 
KSHV infection might, albeit rarely, occur in countries where KSHV is endemic. More studies, with 
larger sample sizes are required to further delineate this route of transmission.  
Breast milk transmission has also been hypothesized to be contributing to KSHV transmission from 
mother to infants. Breast milk has been reported to contain herpesviruses, such as CMV, EBV, and 
HHV-7 [47–51]. Both CMV and KSHV are known to infect monocytes, macrophages, and epithelial 
cells. These cells are found in the cellular components of mature milk suggesting that KSHV might 
also be found in breast milk. Indeed, a study by Dedicoat et al. has shown that KSHV DNA could be 
detected in 12/43 breast milk samples from South African mothers [52]. Our laboratory has 
investigated the presence of KSHV DNA both in breast milk cells and in the liquid portion of breast 
milk (supernatant) [53]. However, we failed to detect any viral DNA in breast milk, whereas EBV 
DNA was readily detectable. Since then, there has been no recent study that has investigated the 
potential of breast milk transmission. Therefore, the current evidence does not point towards breast 
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milk transmission being an important route of horizontal KSHV transmission from the mothers to their 
infants, at least in Zambia.  
The high prevalence of KSHV infection reported by many studies, especially those conducted in 
African children cannot be explained by transmission routes discussed above; vertical mother to child 
transmission, breast milk transmission or via blood contamination. Therefore, another major horizontal 
route of transmission that needs to be investigated is salivary transmission. Indeed, several interesting 
studies indicated that saliva as the likely candidate, which mediates childhood transmission. Soon after 
its discovery, there were studies that reported the presence of KSHV DNA sequences in saliva [54–56]. 
In 2000, Pauk et al. reported that oral exposure to infectious saliva was a potential risk factor for the 
acquisition of KSHV among men who have sex with men. Since then, our group and others have 
conducted several studies to show that KSHV is shed in saliva of infected individuals regardless of 
their HIV-1 status [53,57]. We have reported that the group of mothers who were not shedding KSHV 
in breast milk, did shed KSHV in saliva (19/65 samples were positive). Other studies have also 
investigated the frequency of shedding over a period [57,58]. The results showed that not all KSHV 
seropositive individuals shed the virus in saliva, and individuals in whom KSHV can be detected can 
range from occasional shedders to daily shedders. All the above studies provided strong evidence that 
horizontal transmission, predominantly via saliva, is the major route of transmission especially in 
endemic countries.  
3. Sources and Risk Factors Associated with Transmission 
Soon after the discovery of KSHV, a majority of the studies conducted in Africa, even though 
cross-sectional in design, indicated that KSHV infection was prevalent in young children [11,59,60]. 
Our cohort studies first started in 1998 with the aim to study the epidemiology of KSHV in Zambia. 
Our group has reported that more than 10 percent of Zambian children may be infected by 12 months 
of age [61]. Other studies, though cross-sectional in design, have also shown that especially in endemic 
regions, primary infection likely occurs in early childhood leading to accumulation of infection. This is 
evident from the observed high seroprevalence during childhood (Table 1). Therefore, it is important 
to understand the source of the transmission of virus to children and the risk factors associated with 
acquisition of infection. The exact risk factors that predispose children to acquisition of KSHV 
infection are still not fully understood but immunosuppression, especially due to HIV-1 infection is a 
major risk factor. The route(s) of transmission most likely varies among populations, and given the 
increasing availability of anti-retroviral therapy (ART) in the high HIV-1 prevalence regions, such as  
sub-Saharan Africa, there is a need to study the effect of ART on transmission to HIV-1 infected 
individuals including children. 
It has been reported that there is an increased prevalence of KSHV antibodies in children of 
mothers shedding high number of viral DNA copies/ml of saliva, suggesting that KSHV in maternal 
saliva may be associated with transmission to the child [62]. As mentioned above, we have observed 
KSHV shedding in maternal saliva. Therefore, it will be important to determine whether the maternal 
KSHV shedding in saliva is important for transmission to children and the specific common practices 
that are associated with transmission of infection. The specific practices that expose individuals, 
especially young children, to salivary transmission still remain to be explored and are a subject of our 
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ongoing research study in Zambia. Other studies also indicate that, in Africa, transmission from 
mother to child and between siblings accounts for a substantial proportion of childhood infections 
[29,60]. Preliminary analysis of our ongoing cohort studies in Zambia reveal that transmission to 
children also occurs in households where no household member is KSHV seropositive, who could 
serve as a source of infection to the child. This indicates that transmission may occur from sources 
outside the family unit. In fact, we found that children from several families have KSHV genotype that 
differed from those of their mothers and other family members, suggesting that they have acquired 
KSHV infection from sources outside the household [63]. Other than these studies from Africa, very 
little is known about transmission of KSHV in children in developed countries, including the United 
States, since the prevalence of childhood infection is low, and the results of reports from these 
countries are conflicting [11].  
Table 1. Selected recent reports summarizing the observed percent seroprevalence of 
KSHV in early childhood. 
Reference (Year) Country Age (Years) Percent Prevalence 
Cao et al. (2014) [21] Xinjiang, China 0.5–5 48.3 
Wakeham et al. (2013) [64] Entebbe, Uganda 1 4 
  2 7 
  3 10 
  4 13 
  5 14 
Butler et al. (2011) [65] Buziika B Parish, Uganda 1.5–2 15.5 
  3–5 22.7 
  6–9 31.6 
  10–13 32.0 
Pfeiffer et al. (2010) [66] Kampala, Uganda 0–4 32.1 
  5–9 37.4 
  10–19 30.6 
 Shirati District, Tanzania 0–4 33.9 
  5–9 33.7 
  10–19 32.4 
 Lagos, Nigeria 0–4 14.6 
  5–9 2.3 
  10–19 83.1 
Butler et al. (2009) [38] Kampala, Uganda 2–8 10–30.6 
The current knowledge about source and route of infection, and risk factors associated with 
acquisition of infection has been summarized in Figure 1. As described in detail above, for young 
children, especially in endemic areas where children can be infected by members from within and 
outside the family mainly via saliva, other routes are possible but may not be the major routes of 
transmission. In addition, factors present both within and outside the household or in the environment 
may also increase the risk of acquisition of infection by the child. In fact it has been reported that 
environmental or ecological factors may be associated with the development of KS. This includes 
geographical areas with volcanic soils, chronic schistosome or other parasite infections, biting flies or 
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contact with phorbol esters or other constituents of plants [67–70]. Whether these factors also increase 
the risk of acquisition of KSHV infection is not known.  
 
 
Figure 1. Pictorial representation of possible sources and risk factors associated with 
acquisition of KSHV infection by children in endemic areas. 
4. Future Research  
The year 2014, marks the 20th year since the discovery of KSHV. This is a time to reflect on the 
great strides achieved towards understanding the biology and epidemiology of KSHV, and look 
towards the future to explore other critical questions that need to be investigated. KSHV pathogenesis 
is an area of active research and animal models have been used to study several aspects of KSHV 
infection and pathogenesis. However, there was no ideal model available to understand KSHV 
transmission, routes of transmission, early events following primary viral infection and its interaction 
with the host particularly regarding disease development. One of the main hurdles was the lack of an 
effective model that supported natural routes of viral infection followed by a long-term sustainable 
infection involving both latent and lytic viral gene expression, and leading to the infection of target 
cells and tissues. There have been several studies that have developed animal models to study KSHV 
infection; they include the non-human primate model. However, primate models are difficult to work 
with and not all reported models were able to establish persistent infection [71,72]. Therefore, there is 
still a great need to develop small animal models, such as a rodent model, which can be used to study 
KSHV infection and pathogenesis efficiently. Such a model will need to have relatively short 
generation time, inexpensive, and easy to manipulate. Additionally, this model needs to support natural 
route of viral infection, a long term sustainable infection involving both latent and lytic viral gene 
expression, and the infection of target tissues and cells that reflect those of human infection. Recently, 
a new generation of humanized mouse, the BLT (bone marrow, liver and thymus) mouse (hu-BLT) has 
been shown to be an excellent model for studying human viral infections [73]. This is the only mouse 
model which can generate the human mucosal immune systems, and a human HLA restricted antigen 
specific humoral and cellular responses [74]. To this effect, our laboratory has recently used this 
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mouse model to study KSHV infection [75]. Our study demonstrated that both latent and lytic viral 
transcripts, as well as viral protein expression in various tissues, including spleen and skin. 
Interestingly, mice could be infected via several routes, including the oral mucosal route. Furthermore, 
we found that KSHV can establish infection in human B cells and macrophages in this model. Our 
study represents the first successful effort to recapitulate KSHV infection in a small animal model via 
a natural route of infection. The hu-BLT mouse could potentially be further developed as a model not 
only for studying the pathogenesis of KSHV in vivo, but can also be applied to study routes and 
mechanisms of KSHV transmission and systemic dissemination.  
As discussed earlier by a number of reports, there is still a lack of a gold standard serological assay 
that is equally effective in detecting anti-KSHV antibodies in KS patients (generally having high 
antibody titers) and in KSHV infected but non-KS individuals (generally having lower antibody titers). 
Lack of such an assay has made it difficult to develop a clearer global picture about KSHV 
epidemiology; since the performance of various assays differs, and it has been difficult to compare 
across studies that also differ in the characteristics of the population and study design. Currently, there 
now are two general platforms of KSHV serologic assays, the ELISA based assay and the 
immunofluorescence-based assay. The ELISA based assays in general involve the use of recombinant 
KSHV structural proteins. Such an assay is objective and of high throughout, readily screening through 
a larger number of samples. However, the common format involves the use of only two or three viral 
proteins, and it is known to underestimate the prevalence of infection in a study population. In 
addition, setting the cutoff is critical because the titers of KSHV antibodies vary greatly between 
different study populations and between geographical locations. Recently, Labo et al. have reported an 
important study about the development of a bead-based multiplex assay that detects antibodies to six 
KSHV antigens [76]. Interestingly, the authors conducted a systematic antigenic analysis of the entire 
KSHV proteome by screening 72 KSHV proteins to understand the seroreactivity pattern. Further 
evaluation of this assay on a larger sample size composed of different study populations may prove 
this approach to be very useful for KSHV serodiagnosis. 
The second KSHV serology platform is immunofluorescence assay (IFA). This assay in general 
utilizes KSHV chronically infected B lymphoma cell lines such BC3 cells, which are latently infected 
with KSHV. These cells are then stimulated by TPA to undergo lytic reactivation so that both lytic and 
latent viral proteins can be expressed effective, and then used for the detection of anti-KSHV 
antibodies in study population using indirect immunofluorescence [77]. There are a number of 
laboratories, including ours, that have used this assay format because of the sensitivity of the assay and 
its ability to detect all viral antigens expressed. Our laboratory has used this assay to conduct a number 
epidemiology studies in different study populations, both in Zambia and China [40,61]. However, such 
an assay is subjective, labor intensive, has low throughput and also required highly experienced 
laboratory personnel, and IFA is not a high throughput assay when compared to ELISAs. Using such 
assays in Zambia, we have observed that children generally have lower titers as compared to adults. 
Development of a more efficient highly sensitive and standardized assay will be important to further 
confirm the seroprevalence of KSHV in different parts of world, especially in non-KS individuals. Use 
of such an assay will also help to confirm whether the currently reported seroreversion in infected 
individuals could be due to a true drop in antibody titers to below detection limit of our current assays, 
or whether there is a true loss of KSHV antibody with time due to the viral latency [41,61].  
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KSHV antibodies, for a large part, has been used to investigate KSHV epidemiology, but there is 
still a need to understand the role of the immune response in preventing KSHV infection, in 
controlling viral infection and the development of the KS in infected individuals. There is also a need 
to further study not only the role of the humoral immune response but the cellular immune response as 
well. For the humoral response, an in-depth understanding of the role broadly protective immune 
response on the control of KSHV infection and development of KS will be important. Two studies 
have quantified the prevalence and titers of neutralizing antibodies (nAb) in KS patients or in KSHV 
infected asymptomatic controls. Both reports have focused on a small number of KS patients from the 
US. One suggested that KS patients had lower titers of neutralizing antibodies compared to 
asymptomatic individuals irrespective of their HIV status [78], while the other study found no 
significant difference between the two groups [79]. In addition, the overall prevalence of nAb in KS 
patients or asymptomatic subjects was found to be low and comparable between KS and asymptomatic 
individuals [79]. Our laboratory has investigated the prevalence and titer of KSHV nAb in a  
cross-sectional cohort of Zambian patients [80]. HIV-1-associated KS patients had a significantly 
higher prevalence of neutralizing antibody response when compared to non-KS but KSHV infected 
individuals. This suggested that viral lytic replication and the resulting antigenemia, which occur 
during KS development, might be essential contributors to development of neutralizing responses. 
However, whether these responses are protective if passively introduced prior to primary KSHV 
infection is currently not known. In addition to nAb, further studies are required to decipher the role of 
cell-mediated immunity in protecting against KSHV infection and preventing the development of KS. 
A major hurdle in this area of research has been a lack of a robust T cell response against KSHV 
antigens. A weak adaptive immune response following primary infection has proved to be the major 
obstacle in this area. However, recent studies have provided some interesting data. One of these studies 
by Lepone et al. is very interesting that has reported on the identification of five novel HLA A*0201-
restricted CD8+ T cell epitopes present in LANA-1, K12, gB, and K8.1 proteins [81]. These epitopes 
induced both single and multiple immune mediators in CD8+ T cells from healthy KSHV seropositive 
individuals. A review by Robey et al. has provided a list of identified epitopes to known KSHV 
immunogenic open reading frames [82]. These are critical steps towards understanding the role of T 
cells in the pathogenesis of KSHV infection though further research in identification of other 
immunodominant epitopes is needed. Further studies are also required to understand the role of  
CD8+ and CD4+ T cell responses to primary infection and disease development. There is a gap  
in our understanding of broad range of antigenic epitopes that can be restricted by other MHC class I 
and II haplotypes.  
 In addition to the immune response against KSHV, there needs to be a better understanding of the 
routes of transmission in different populations, the risk factors associated with incident infection and 
the potential source(s) of transmission. This information is pertinent in the public health disease 
management for the design of strategies to prevent KSHV infection, especially in endemic regions. 
Prevention of transmission to high-risk individuals in Western countries and to children in endemic 
areas, especially in Africa, may be the best approach to reduce the burden of infection and the 
subsequent development of KS. We believe that further work in understanding local risk factors and 
sources of transmission will lead to the development of strategies to prevent transmission of infection 
to susceptible individuals. 
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In parallel to the development of public health policy to prevent KSHV infection, there is  
also a need towards the development of protective vaccines since vaccination is the most efficient 
method to eliminating viral infectious agents and to curb the epidemic. However, there are ongoing 
discussions among researchers and policy makers whether such a vaccine is needed for KSHV since 
the KS incidence is decreasing because of the effectiveness of the ART, at least in the developed 
countries [83,84]. However, due to the high prevalence of KSHV in the African countries and in other 
KS endemic regions, it is questionable whether ART and other public health prevention strategies will 
be effective in preventing KSHV infection and the subsequent risk in developing KS. Therefore, there 
is a still a continuous need to better understand the viral antigens and the generation of protective 
immune response against KSHV antigens. Such an understanding will be a first step towards 
developing a protective KSHV vaccine.  
In addition to the need to prevent epidemic KS due to its sudden rise in concordance to the AIDS 
epidemic, there is a severe lack of information about the endemic KS. This form of KS is still 
prevalent in many parts of Africa and its epidemiology and pathogenesis needs to be better 
characterized. It is most likely that the endemic KS will continue to persist in these regions due to the 
high prevalence of KSHV infection, even in the HIV-1 uninfected population. We have recently 
conducted a study at the Dermatology and Venereology clinic at University Teaching Hospital, 
Lusaka, Zambia, which is a national referral clinic for all suspected KS cases. From 2008 to 2013, we 
document 726 pathologist confirmed KS cases at this clinic [85]. Of these, one third of cases were 
diagnosed in HIV negative patients (endemic KS). This underscores the need to understand the 
epidemiology of endemic form of KS in this region. Currently, there is a gap in the literature regarding 
the incidence of endemic KS, whether prevalence is stable or increasing, risk factors associated with 
development of endemic form of KS. Up to now endemic KS has received little attention because it is 
overshadowed by the recent epidemic KS, especially when a number of studies have reported a 
decrease in epidemic KS incidence in anti-retroviral treated HIV positive patients, even though they 
are mostly occurring in the developed countries [83,85,86]. Our study in Zambia clearly shows that the 
endemic KS is still prevalent and it is likely that antiretroviral therapy will have little or no impact on 
its incidence. Therefore, it is likely that endemic areas will continue to bear the burden of endemic KS. 
Furthermore, while great strides have been taken in increasing the coverage of ART in HIV-1 positive 
patients, the degree of coverage in different African countries varies. Therefore, to further reduce 
epidemic KS in areas that are endemic for KS (such as the “KS belt” in Africa) without complete ART 
coverage may even prove difficult in the near future. Our study in Zambia and other studies have 
clearly shown that classic and endemic forms of KS are more prevalent in males as compared to 
females [85,87]. These observations also raise the question that genetic factors linked to gender may 
have a role in progression to KS.  
While conducting our cohort studies in Zambia, we have observed that laboratory research findings 
have yet to be translated into public health practices and programs to reduce transmission of KSHV. 
Health care professionals are often not aware of KSHV and its link to KS, and current research in this 
field and better programs similar to human papilloma virus, hepatitis B virus and HIV-1 prevention 
need to be developed. Educational programs focusing on prevention of transmission are especially 
needed in endemic regions with limited resources for treatment of KS. It is imperative that results of 
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laboratory research be translated into effective health behavior interventions for prevention of KSHV 
infection and for overall community health promotion. 
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